Promoted Content
Promoted Content

Find Novel Neurology Drugs in Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): K102

            Therapeutic Area: Neurology Product Name: K102

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Amneal Pharmaceuticals

            Deal Size: $108.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition January 12, 2021

            Details:

            The acquisition enhances Amneal's R&D expertise with the addition of the Kashiv Specialty team and its impressive track record in developing complex generic products (e.g. Yuvafem and EluRyng) and innovative drug delivery technologies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hydroxylated Sulfamides derivatives

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Neuropathix

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition December 21, 2020

            Details:

            Neuropathix has acquired novel hydroxylated sulfamides from Advanced Neural Dynamics and Fox Chase Chemical Diversity Center. These acquisitions provide Neuropathix another exciting avenue for strong clinical pipelines.

            Queen Mary University of London

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cladribine

            Therapeutic Area: Neurology Product Name: Mavenclad

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 19, 2020

            Details:

            The Phase 2 clinical trial, ChariotMS, will test whether Mavenclad (cladribine) can slow a worsening of hand and arm function in people with progressive multiple sclerosis (MS) and very limited walking abilities.

            Oscine

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Glial progenitor cell therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Sana Biotechnology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition October 30, 2020

            Details:

            The combination will integrate Oscine’s glial progenitor cell program and underlying technologies together with Sana’s broader platform and programs. Terms of the acquisition were not disclosed.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cladribine

            Therapeutic Area: Neurology Product Name: CRD1

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Omega Funds

            Deal Size: $16.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing October 13, 2020

            Details:

            The financing will allow the company to progress CRD1 through Phase 2 proof of concept clinical development. The potential of CRD1 to address unmet medical needs in rare autoimmune disorders was identified by Chord Therapeutics‘ founder, Dr. Arthur Roach.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Topiramate

            Therapeutic Area: Neurology Product Name: ET-101

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 06, 2020

            Details:

            Marketing Application for ET-101 was submitted for monotherapy to treat primary general tonic-clonic seizures in patients at least two years old, adjunctive therapy for treatment of partial-onset seizures, and as preventative treatment of migraine in patients, two years old.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CRISPR based gene therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Biogen

            Deal Size: $415.0 million Upfront Cash: $15.0 million

            Deal Type: Collaboration October 06, 2020

            Details:

            Under the terms of the collaboration, Scribe will work with Biogen to create therapeutics for genetically-driven ALS, with an option to pursue an additional neurological disease target with high, unmet need.

            Progreso y Salud Foundation

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SV40 vector based gene therapy

            Therapeutic Area: Neurology Product Name: SVec

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Amarna Therapeutics

            Deal Size: $0.7 million Upfront Cash: Undisclosed

            Deal Type: Collaboration September 25, 2020

            Details:

            The collaboration is a joint effort between the research group of the FPS at research institute Cabime and Amarna Therapeutics which aims to assess the efficacy of SVec in reducing the immune responses that trigger the damage and loss of myelin in animal models of MS.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Neurology Product Name: BB106

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bexson Biomedical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 21, 2020

            Details:

            The collaboration will focus on developing a customized version of the SG EZ-be Pod®, a wearable drug delivery device, for Bexson’s proprietary ketamine formulation, BB106.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Butorphanol,Azaperone,CAS 86347-15-1

            Therapeutic Area: Neurology Product Name: BAM Kit

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Wedgewood Pharmacy

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition August 10, 2020

            Details:

            ZooPharm’s BAM™ Kit includes a patented combination of Butorphanol tartrate, Azaperone tartrate, and Medetomidine hydrochloride that is used to immobilize a broad range of species.

            PharmaCompass